Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

March 21, 2018March 21, 2018

Medicinal Cannabis Safe and Effective for Pain, Chemo Side Effects, Journal Says

News

The supervised use of medicinal cannabis is safe and effective at relieving pain and reducing chemotherapy-induced nausea and vomiting in cancer patients, an increasing body of research data shows. In ... Read more

March 16, 2018

Trial to Explore Benefits of Exercise Before Autologous Stem Cell Transplant in Myeloma Patients

News

A new clinical trial will determine if an exercise program before an autologous stem cell transplant can improve treatment-related side effects in multiple myeloma patients. The trial details are summarized ... Read more

March 14, 2018March 14, 2018

Seattle Genetics Starts Phase 1 Trial Testing SGN-CD48A in Relapsed or Refractory Myeloma

News

Seattle Genetics‘ investigational therapy SGN-CD48A, being evaluated in a Phase 1 clinical trial for relapsed or refractory multiple myeloma, was successfully delivered to the trial’s first patient, the company ... Read more

March 12, 2018March 12, 2018

Patients with MGUS Have a Low But Persistent Risk of Multiple Myeloma, Study Finds

News

Patients with a condition called monoclonal gammopathy of undetermined significance, characterized by the presence of the abnormal monoclonal or M protein, have a small but persistent risk of multiple myeloma or ... Read more

January 24, 2018

FDA to Give Priority Review to Darzalex Combinations for Multiple Myeloma

News

The U.S. Food and Drug Admnistration will give priority review to Darzalex (daratumumab) as an add-on to standard treatments for multiple myeloma patients who cannot have a stem cell transplant. ... Read more

January 17, 2018January 17, 2018

Gamida Recruiting Myeloma Patients for Phase 1 Trial of Its Killer Cells-based Therapy

News

Gamida Cell is enrolling participants in a Phase 1 clinical trial of an immunotherapy for myeloma and non-Hodgkin’s lymphoma that is based on expanding the number of the body’s natural ... Read more

December 18, 2017

CellProtect Receives EU Orphan Drug Status for Treatment of Multiple Myeloma

News

The European Commission has granted orphan drug status to CellProtect as a treatment for multiple myeloma, according to the investigational therapy’s developer, CellProtect Nordic Pharmaceuticals. Using patients’ own blood ... Read more

December 6, 2017

Ascentage Gets FDA Nod to Advance APG-1387 into Clinical Trials for Myeloma, Other Cancers

News

The U.S. Food and Drug Administration (FDA) has accepted Ascentage Pharma‘s Investigational New Drug (IND) application for APG-1387, allowing Ascentage to test the anti-cancer drug candidate in clinical trials. APG-1387 ... Read more

November 1, 2017November 1, 2017

Poseida Awarded $19.8M Grant to Continue Developing P-BCMA-101 for Multiple Myeloma

News

The California Institute for Regenerative Medicine (CIRM) awarded a $19.8 million grant to Poseida Therapeutics to support the clinical development of their P-BCMA-101 investigational immunotherapy for relapsed and refractory ... Read more

October 18, 2017

Darzalex Now Available to Certain Myeloma Patients in Scotland Through its NHS

News

The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by National Health Service (NHS) in Scotland, has amended its initial decision and now recommends Janssen’s Darzalex (daratumumab) for ... Read more